The document summarizes the roles and structure of J.P. Morgan's CIO unit, including managing the bank's pension fund and surplus cash, asset-liability management, and taking advantage of positioning opportunities. It also notes that other banks like HSBC and Goldman Sachs have similar units responsible for tasks like ALM management, credit portfolio management, and some proprietary trading. A chart shows the CIO unit's quarterly revenues and value-at-risk over time, with revenues coming from ALM/net interest income, proprietary/principal trading, and securities gains.
1 of 2
Download to read offline
More Related Content
JPM\'s CIO Unit
1. Market Update: Theme
J.P.Morgan¡¯s CIO Unit Organisational Structure of CIO unit
We have been tracking J.P.Morgan¡¯s CIO unit for the last two
years. Our sources suggest its roles include:
CFO
¡ì? managing JPM's defined benefit pension scheme,
¡ì? investing in securities with surplus cash that the bank
holds (e.g. from cheap financing opportunities),
¡ì? managing ALM risk (under guidance from group Chief Investment Group
treasury), and Officer Treasury
¡ì? taking advantage of positioning opportunities.
JPM is not the only bank to have a structure like this. HSBC
have a Balance Sheet Management group within Global US Defined Benefit
Markets and Banking which carries out ALM management, Pension Plan
credit portfolio management, money markets trading and
some positioning activities. At Goldman Sachs the Corporate Corporate
Treasury Unit - run by Liz Beshel - is arguably the nerve Acquisitions
centre of the bank; carrying out strategic analysis, regulatory
engagement, risk management and oversight and some prop Asset & Liability
trading. Management
Prop Traders
J.P.Morgan CIO unit: quarterly revenues and VaR
Revenue Quarterly Revenues and VaR of JPM CIO Unit VaR
US$ million 95% confidence
2,500 90
80
2,000
70
1,500 60
50
1,000
40
500 30
20
-
4Q09 1Q10 2Q10 3Q10 4Q10 1Q11 2Q11 3Q11 4Q11 1Q12
10
-500 0
ALM/NII Prop/Principal Securities Gains VaR (RHS)
Source: J.P.Morgan, Tricumen analysis
1/2 2 May 2012
2. Market Update
Notes & Caveats
Tricumen Limited has used all reasonable care in writing, editing and presenting the information found in this report. All
reasonable effort has been made to ensure the information supplied is accurate and not misleading. For the purposes of cross-
market comparison, all numerical data is normalised in accordance to Tricumen¡¯s proprietary product classification and may
contain +/-10% margin of error.
The information and commentary provided in this report has been compiled for informational purposes only. We recommend
that independent advice and enquiries should be sought before acting upon it. Readers should not rely on this information for
legal, accounting, investment, or similar purposes. No part of this report constitutes investment advice, any form of
recommendation, or a solicitation to buy or sell any instrument or to engage in any trading or investment activity or strategy.
Tricumen does not provide investment advice or personal recommendation, nor will it be deemed to have done so.
Tricumen Limited makes no representation, guarantee or warranty as to the suitability, accuracy or completeness of the report
or the information therein. Tricumen Limited assumes no responsibility for information contained in this report and disclaims all
liability arising from negligence or otherwise in respect of such information.
Tricumen Limited is not liable for any damages arising in contract, tort or otherwise from the use of or inability to use this
report or any material contained in it, or from any action or decision taken as a result of using the report.
2/2 2 May 2012